Autres langues IN8bio, Inc.

Actions

INAB

US45674E1091

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/06/2024			Varia. 5j.	Varia. 1 janv.
0,8789 ^USD	-1,80 %		-4,49 %	-36,31 %

14/06	IN8BIO, INC. : JonesTrading Institutional Services persiste à l'achat	ZM
13/06	IN8bio, Inc. approuve les nominations au conseil d'administration	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference	24/06
IN8bio, Inc. Approves Directorate Appointments	13/06
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100	13/06
IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100	13/06
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting	03/06
IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting	03/06
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024	24/05
IN8bio Plans to Report Improvement in Progression-Free Survival of Newly Diagnosed Patients With Glioblastoma Multiforme	24/05
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting	23/05
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress	14/05
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024	13/05
In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024	13/05
IN8bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	09/05
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma	30/04
In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma	30/04
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene and Cell Therapy 2024 Annual Meeting	25/04
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	24/04
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	16/04
Top Premarket Gainers	10/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues IN8bio, Inc.

Actions

INAB

US45674E1091

Autres langues

Filtres